Results 131 to 140 of about 5,926 (192)

PARP inhibitors and breast cancer: from therapeutic breakthrough to resistance challenge. [PDF]

Exp Mol Med
Wang W, Cai C, Qin S, He L, Liang Q, Tang S, Xie J, Long T, Hou J, Kim W, Zhao F.   +10 more
europepmc   +1 more source

Aurora kinase B phosphorylates ZBP1 to drive PANoptosis following treatment with PARP and ATR inhibitors combination. [PDF]

Nat Commun
Gong W, Liao Z, Xiong F, Wang L, Shi S, Luo M, Zhang Y, Xu Q, Wang Y, Wu Y, Zhu L, Kuang D, Labrie M, Mills GB, Ma D, Liu D, Zhao GN, Gao Q, Fang Y.   +18 more
europepmc   +1 more source

Matching-adjusted indirect comparisons of PARP inhibitor combinations in metastatic castration-resistant prostate cancer across key populations. [PDF]

Oncologist
Castro E, Wang D, Paganelli S, Haltner A, Su N, Kirker M, Chang J, Samjoo IA.   +7 more
europepmc   +1 more source

Population pharmacokinetic analyses for talazoparib (TALA) in cancer patients

Annals of Oncology, 2018
Y. Yu, C. Durairaj, H. Shi, D.D. Wang
openaire   +1 more source

Talazoparib for prostate cancer and breast cancer

Australian prescriber
  +5 more sources

Targeting poly(ADP-ribose) polymerase in metastatic prostate cancer: current landscape and future directions. [PDF]

Curr Opin Oncol
Shi X, Rifai S, Meher Z, Hussain A.
europepmc   +1 more source

PARP inhibitor resistance in IDH1-mutant cancers due to loss of end protection factors, 53BP1 and REV7. [PDF]

NAR Cancer
Colón-Ríos DA, Dow J, Krysztofiak A, Liu Y, Rogers FA, Glazer PM.   +5 more
europepmc   +1 more source

Efficacy at a cost?-quality of life implications of PARP inhibition in the homologus recombination repair (HRR) cohort of TALAPRO-2. [PDF]

Transl Androl Urol
Esteban-Villarrubia J, Castro E.
europepmc   +1 more source

Interplay Between Poly(ADP-ribosyl)ation and Specific Inner Cellular Events That Suggest Combination Strategies for Overcoming PARP Inhibitor Resistance. [PDF]

Pharmaceutics
Xu L, Kong X, Zhang B, Ma H, Li X, Deng Y, Liu W, Ren W, Tang X, Zhang D.   +9 more
europepmc   +1 more source

Cost-effectiveness of talazoparib plus enzalutamide as first-line therapy in metastatic castration-resistant prostate cancer. [PDF]

Ther Adv Med Oncol
Zhu J, Li Z, Ding Y, Xu Q.
europepmc   +1 more source